UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research

Nature reviews. Cancer, 2013-04, Vol.13 (4), p.273-282

2013

Volltextzugriff (PDF)

Beyond chemotherapy: targeted therapies in ovarian cancer

Nature reviews. Cancer, 2009-03, Vol.9 (3), p.167-181

2009

Volltextzugriff (PDF)

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet (British edition), 2016-03, Vol.387 (10023), p.1066-1074

2016

Volltextzugriff (PDF)

Ovarian cancer: strategies for overcoming resistance to chemotherapy

Nature reviews. Cancer, 2003-07, Vol.3 (7), p.502-516

2003

Volltextzugriff (PDF)

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

Journal of clinical oncology, 2012-02, Vol.30 (4), p.372-379

2012

Volltextzugriff (PDF)

Emerging therapeutic targets in endometrial cancer

Nature reviews. Clinical oncology, 2011-05, Vol.8 (5), p.261-271

2011

Volltextzugriff (PDF)

Rethinking ovarian cancer: recommendations for improving outcomes

Nature reviews. Cancer, 2011-10, Vol.11 (10), p.719-725

2011

Volltextzugriff (PDF)

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

Journal of clinical oncology, 2010-05, Vol.28 (15), p.2512-2519

2010

Volltextzugriff (PDF)

Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2009-08, Vol.27 (23), p.3742-3748

2009

Volltextzugriff (PDF)

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

Journal of clinical oncology, 2008-10, Vol.26 (28), p.4563-4571

2008

Volltextzugriff (PDF)

Making the best of PARP inhibitors in ovarian cancer

Nature reviews. Clinical oncology, 2010-09, Vol.7 (9), p.508-519

2010

Volltextzugriff (PDF)

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Journal of clinical oncology, 2006-06, Vol.24 (16), p.2505-2512

2006

Volltextzugriff (PDF)

Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers

PloS one, 2012-11, Vol.7 (11), p.e47020-e47020

2012

Volltextzugriff (PDF)

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

Journal of clinical oncology, 2011-04, Vol.29 (10), p.1271-1279

2011

Volltextzugriff (PDF)

Imaging ovarian cancer and peritoneal metastases-current and emerging techniques

Nature reviews. Clinical oncology, 2010-07, Vol.7 (7), p.381-393

2010

Volltextzugriff (PDF)

Reversal of drug resistance in ovarian cancer: where do we go from here?

Journal of clinical oncology, 2008-06, Vol.26 (16), p.2616-2618

Kaye, Stan B

2008

Volltextzugriff (PDF)

Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey

European journal of cancer (1990), 2014-08, Vol.50 (12), p.2050-2056

2014

Volltextzugriff (PDF)

Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer

EMBO molecular medicine, 2021-05, Vol.13 (5), p.e13366-n/a

2021

Volltextzugriff (PDF)

Weekly paclitaxel in the treatment of recurrent ovarian cancer

Nature reviews. Clinical oncology, 2010-10, Vol.7 (10), p.575-582

2010

Volltextzugriff (PDF)

Does Aggressive Surgery Only Benefit Patients With Less Advanced Ovarian Cancer? Results From an International Comparison Within the SCOTROC-1 Trial

Journal of clinical oncology, 2005-12, Vol.23 (34), p.8802-8811

2005

Volltextzugriff (PDF)

PARP inhibitors: the race is on

British journal of cancer, 2016-03, Vol.114 (7), p.713-715

2016

Volltextzugriff (PDF)

Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors

Journal of clinical oncology, 2012-03, Vol.30 (9), p.996-1004

2012

Volltextzugriff (PDF)

The Bcl-2/Bcl-XL Family Inhibitor ABT-737 Sensitizes Ovarian Cancer Cells to Carboplatin

Clinical cancer research, 2007-12, Vol.13 (23), p.7191-7198

2007

Volltextzugriff (PDF)

Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype

Journal of clinical oncology, 2010-05, Vol.28 (15), p.2505-2511

2010

Volltextzugriff (PDF)

1 – 25 von 125

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(116)
Mit Volltextzugriff
(108)

Publikationsform

Sprache

Englisch
(125)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(95)
Life Sciences & Biomedicine
(94)
Humans
(92)
Oncology
(82)
Female
(76)
Middle Aged
(47)
Adult
(43)
Aged
(43)
Biological And Medical Sciences
(43)
Medical Sciences
(42)
Ovarian Neoplasms - Drug Therapy
(37)
Tumors
(36)
Male
(33)
Ovarian Cancer
(30)
Pharmacology. Drug Treatments
(27)
Treatment Outcome
(26)
Neoplasms - Drug Therapy
(25)
Antineoplastic Agents
(22)
Antineoplastic Agents - Therapeutic Use
(19)
Ovarian Neoplasms - Pathology
(18)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research

Beyond chemotherapy: targeted therapies in ovarian cancer

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial

Ovarian cancer: strategies for overcoming resistance to chemotherapy

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer

Emerging therapeutic targets in endometrial cancer

Rethinking ovarian cancer: recommendations for improving outcomes

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

Making the best of PARP inhibitors in ovarian cancer

Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

Imaging ovarian cancer and peritoneal metastases-current and emerging techniques

Reversal of drug resistance in ovarian cancer: where do we go from here?

Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey

Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer

Weekly paclitaxel in the treatment of recurrent ovarian cancer

Does Aggressive Surgery Only Benefit Patients With Less Advanced Ovarian Cancer? Results From an International Comparison Within the SCOTROC-1 Trial

PARP inhibitors: the race is on

Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors

The Bcl-2/Bcl-XL Family Inhibitor ABT-737 Sensitizes Ovarian Cancer Cells to Carboplatin

Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype

Suchergebnisse filtern